Genmab (GMAB) announced a partnership with Anthropic to advance and enhance its research and development processes through the adoption of artificial intelligence capabilities. Under the agreement, Genmab and Anthropic will design and deploy custom, Claude-powered agentic AI solutions to support clinical development priorities. Genmab’s teams will use Claude to accelerate data processing, analysis, and document generation.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GMAB:
- Genmab price target raised to DKK 2,400 from DKK 2,000 at Deutsche Bank
- Genmab price target raised to DKK 2,500 from DKK 2,000 at Barclays
- Genmab: Late-Stage Oncology Pipeline Catalysts Underpin Buy Rating and Upside Potential
- Genmab discontinuing acasunlimab a ‘good decision,’ says Guggenheim
- Genmab Drops Acasunlimab to Refocus Investment on Late-Stage Cancer Pipeline